The Fund Grade · free · no account needed
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Boston Partners Global Equity Institutional Class
#115 of 500 graded active funds · blend · mid segment peer group
The point · specialist footprint
BPGIX puts less of its book behind proven specialists than 68% of graded funds.
Bottom 20%
● Bottom 40%
Middle
Top 40%
Top 20%
That has mattered: over the past 2.7 years, funds with this little specialist backing trailed top-rung funds by about 3.8% per quarter and beat the S&P in only 22% of fund-quarters. If it also charges an active fee, the higher-graded alternatives deserve a look.
10,000+ funds tracked · the graded specialists among them drive every read
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
BPGIX vs the Honor Roll · share card ↗Conviction exposure
12.3%
of the book in specialist-converged names
Late-stage weight
26.1%
of the book in Crowded or Fading names
Active share
96.4%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
BPGIX earns an A grade and ranks 115 of 500 graded funds, with specialists making early conviction bets on DIS, FCX, and BAC. The concern is a cluster of fading positions including CVS, CI, and TXT, where specialist investors are already heading for the exit.
→ Watch CVS, CI, and TXT closely, as specialists are fading all three and together they represent meaningful weight.
→ Note the early conviction calls on DIS, FCX, and BAC as the clearest evidence of where this fund sees unpriced opportunity.
Support leaving these positions
Read from today's disclosed book. Evidence, not advice.